血清指标对卵巢恶性肿瘤早期诊断价值的研究进展

Abstract
Figure/Table
References (33)
Related Citation (6)

Download: PDF (0 KB) HTML (41 KB)
Export: BibTeX | EndNote (RIS)

Abstract For lung cancer,breast cancer,liver cancer,colorectal cancer,pancreatic cancer and many other solid malignancies,serum carbohydrate antigen 125 (CA125),human epididymal protein 4 (HE4),ratio of platelets to lymphocytes (PLR),and the ratio of neutrophil to lymphocytes (NLR) have been widely studied,and their value have been confirmed by a large number of studies,but there have been few studies on ovarian malignancies.Existing studies have found that serum CA125,HE4,PLR and NLR have certain value in the early diagnosis of ovarian malignant tumors,but there is no unified understanding.So far,there is no accepted sensitive indicator for the early diagnosis of ovarian malignancies.The purpose of this review is to summarize the available evidence.

Key words： Ovarian malignant tumor Carbohydrate antigen 125 Human epididymal protein 4 Ratio of platelets to lymphocytes Ratio of neutrophils to lymphocytes

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Zhi-min
	LIU Zhi-qiang
	GUO Qing-zhi
	SUN Li
	SHI Hong-tang

Cite this article:

WANG Zhi-min,LIU Zhi-qiang,GUO Qing-zhi, et al. Advances in the value of serum index in early diagnosis of ovarian malignant tumor[J]. 中国当代医药, 2020, 27(14): 30-33.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I14/30

[33]	田菁.外周卵巢癌标志物的基础及临床研究[D].天津：天津中医药大学，2018.
[2]	李克敏，尹如铁.复发性卵巢癌的化学治疗[J].实用妇产科杂志，2017，33（11）：815-818.
[3]	Leitao MM Jr.Management of epithelial ovarian cancer[J].Clin Adv Hematol Oncol，2018，16（10）：656-659.
[5]	范亚平，孙黎，牛爱军，等.血清人附睾蛋白4、CA125在卵巢癌诊断中的价值[J].山东医药，2014，54（29）：64-65.
[32]	Zhao T，Hu W.CA125 and HE4：measurement tools for ovarian cancer[J].Gynecol Obstet Invest，2016，81：430-435.
[1]	Ledermann JA，Raja FA，Fotopoulou C，et al.Newly diagnosed and relapsed epithelial ovarian carcinoma：Esmo clinical practice guidelines for diagnosis，treatment and follow-up[J].Ann Oncol，2018，29（Suppl 4）：iv259.
[4]	Azzam AZ，Hashad DI，Kamel NA.Evaluation of HE4 as an extrabio marker to improve detection of ovarian carcinoma：is it time for a stepforward？[J].Arch Gynecol Obstet，2013，288（1）：167-172.
[6]	Prodromidou A，Andreakos P，Kazakos C，et al.The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophilto-lymphocyte ratio in ovarian cancer[J].Inflamm Res，2017，66（6）：467-475.
[7]	Chen FW，Shen J，Wang JW，et al.Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors：diagnostic value of the combined use of HE4，CA125，CA19-9，and CEA in ovarian tumors [J].Cancer Manag Res，2018，10：1313-1318.
[8]	Fu Y，Wang X，Pan Z，et al.Clinical outcomes and prognostic factors of patients with epithelial ovarian cancer subjected to first-line treatment：a retrospective study of 251 cases[J].Front Med，2014，8（1）：91-95.
[9]	Nicholson BD，Lee MM，Wijeratne D，et al.Trends in cancer antigen 125 testing 2 2003-2014：A primary care population-based cohort study using laboratory data[J].Eur J Cancer Care（Engl），2019，28（1）：e12 914.
[10]	Ingegerd Helistrom，Raycraft J，Haydenledbetter M，et al.The HE4（WFDC2）protein is a biomarker for ovarian carcinoma[J].Cancer Res，2003，63（13）：3695.
[11]	Drapkin R.Human epididymis protein 4（HE4）is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas[J].Cancer Res，2005，65（6）：2162-2169.
[12]	Delic R，Stefanovic M，Krivec S，et al.Comparison of HE4 and CA125 levels in women with benign gynecologic disorders：Does age or menopausal status matter[J]Wien Klin Wochenschr，2016，128（Suppl 7）：543-547.
[13]	Moore RG，Plante B，Hartnett E，et al.Assessment of serum HE4 levels throughout the normal menstrual cycle[J].Am J Obstet Gynecol，2017，217（1）：51-53.
[14]	Guo YX，Neoh KH，Chang XH，et al.Diagnostic value of HE4+circulating tumor cells in patients with suspicious ovarian cancer[J].Oncotarget，2018，9（7）：7522-7533.
[15]	Dewan R，Dewan A，Jindal M.Diagnostic performance of serum human epididymis protein 4（HE4）for prediction of malignancy in ovarian masses[J].Asian Pac J Cancer Prev，2019，20（4）：1103-1108.
[16]	Brenk A，Bodzek P，Balis M，et al.Usefulness of HE4 protein in differentiation of pelvic masses in woman[J].Prz Menopauzalny，2019，18（1）：27-32.
[17]	Shen J，Zhu Y，Wu W，et al.Prognostic role of neutrophilto-lymphocyte ratio in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy[J].Med Sci Monit，2017，23：315-324.
[18]	Prabawa IPY，Bhargah A，Liwang F，et al.Pretreatment neutrophil-to-lymphocyte ratio（NLR）and platelet-to-lymphocyte ratio（PLR）as a predictive value of hematological markers in cervical cancer[J].Asian Pac J Cancer Prev，2019，20（3）：863-868.
[19]	Kokcu A，Kurtoglu E，Celik H，et al.May the platelet to lymphocyte ratio be a prognostic factor for epithelial ovarian cancer？[J].Asian Pac J Cancer Prev，2014，15（22）：9781-9784.
[20]	Yildirim MA，Seckin KD，Togrul C，et al.Roles of neutrophil/lymphocyte and platelet/lymphocyte ratios in the early diagnosis of malignant ovarian masses[J].Asian Pac J Cancer Prev，2014，15（16）：6881.
[21]	Yildirim M，Demir Cendek B，Filiz Avsar A.Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-tolymphocyte ratios[J].Mol Clin Oncol，2015，3（2）：317-321.
[22]	Bakacak M，Serin S，Ercan O，et al.Utility of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios to distinguish malignant from benign ovarian masses[J].J Turk Ger Gynecol Assoc，2016，17（1）：21.
[23]	Ozaksit G，Tokmak A，Kalkan H，et al.Value of the platelet to lymphocyte ratio in the diagnosis of ovarian neoplasms in adolescents[J].Asian Pac J Cancer Prev，2015，16（5）：2037-2041.
[24]	Kemal Y，Demirag G，Ekiz K，et al.Mean platelet volume could be a useful biomarker for monitoring epithelial ovarian cancer[J].J Obstet Gynaecol，2014，34（6）：515-518.
[25]	Zhou Q，Hong L，Zuo M Z，et al.Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer：evidence from 4，910 patients[J].Oncotarget，2017，8（40）：68 938-68 949.
[26]	Wu YY，Qin YY，Qin JQ，et al.Diagnostic value of derived neutrophil-to-lymphocyte ratio in patients with ovarian cancer[J].J Clin Lab Anal，2019，33（4）：e22 833.
[27]	Polat M，Senol T，Ozkaya E，et al.Neutrophil to lymphocyte and platelet to lymphocyte ratios increase in ovarian tumors in the presence of frank stromal invasion[J].Clin Transl Oncol，2016，18（5）：457-463.
[28]	Bednarska K，Klink M，Wilczyński JR，et al.Heterogeneity of the Mac-1 expression on peripheral blood neutrophils in patients with different types of epithelial ovarian cancer[J].Immunobiology，2015，221（2）：323-332.
[29]	Kemal Y，Demirag G，Ekiz K，et al.Mean platelet volume could be a useful biomarker for monitoring epithelial ovarian cancer[J].J Obstet Gynaecol，2014，34（6）：515-518.
[30]	Yilmaz E，Coskun EI，Sahin N，et al.MPV，NLR，and platelet count；new hematologic markers in diagnosis of malignant ovarian tumor[J].Eur J Gynaecol Oncol，2017，38（3）：346-349.
[31]	Dochez V，Caillon H，Vaucel E，et al.Biomarkers and algorithms for diagnosis of ovarian cancer：CA125，HE4，RMI and ROMA，a review[J].J Ovarian Res，2019，12（1）：28.